Skip to main content
. 2021 Jun 28;15:2815–2830. doi: 10.2147/DDDT.S281639

Table 4.

Treatment Emergent Adverse Events for Various Regimens

Regimen PaMZ n=148 BPaZ n=119 BPaMZ n=60 BPaL n=109 HRZE n=120
Trial NIX-TB
Nausea 30 (20.3%) 4 (3.4%) 5 (8.3%) 40 (36.7%) 8 (6.7%)
Vomiting 18 (12.2%) 5 (4.2%) 7 (11.7%) 37 (33.9%) 11 (9.2%)
Diarrhea 10 (6.8%) 4 (3.4%) 3 (5%) 11 (10.1%) 3 (2.5%)
Abdominal pain/dyspepsia 9 (6.1%) 37 (34%) 3 (2.5%)
Decreased appetite 24 (22.0%)
Abnormal weight loss 11 (10.1%)
Liver disorder 33 (22.3%) 9 (7.5%)
Enzyme abnormality 7 (4.7%) 4 (3.3%)
ALT increased 8 (6.7%) 2 (3.3%) 10 (9.2%) 2 (1.7%)
AST increased 6 (5%) 3 (5%) 9 (8.3%) 3 (2.5%)
Amylase increased 10 (16.7%) 1 (0.8%)
GGT increased 2 (1.7%) 6 (10%) 19 (17.4%)
Anemia 5 (4.2%) 1 (1.7%) 40 (36.7%)
Leukocytosis 9 (6.1%) 3 (2.5%)
Hyperkalemia or hyponatremia 13 (8.8%) 8 (6.7%)
Glucose abnormality 9 (6.1%) - hyper 12 (11%)-hypo 3 (2.5%)- hyper
Hypoalbuminemia 6 (4.1%) 5 (4.2%)
Hyperuricemia 42 (28.4%) 28 (23.5%) 27 (45%) 26 (21.7%)
Dizziness 15 (10.1%) 4 (3.4%) 1 (1.7%) 5 (4.2%)
Headache 14 (9.5%) 30 (27.5%) 2 (1.7%)
Peripheral sensory neuropathy* 76 (69.7%)
Myalgia 7 (5.9%) 3 (5%) 1 (0.8%)
Arthralgia 38 (25.7%) 15 (12.6%) 13 (21.7%) 17 (14.2%)
Extremity or back pain 2 (1.7%) 4 (6.7%) 13 (11.9%)
Acne 17 (15.6%)
Rash 3 (2.5%) 1 (1.7%) 17 (15.6%) 2 (1.7%)
Pruritus generalized 8 (6.7%) 2 (3.3%) 8 (6.7%)
Pruritis 8 (5.4%) 5 (4.2%) 2 (3.3%) 16 (14.7%) 8 (6.7%)
Hemoptysis 4 (3.4%) 6 (10%) 14 (12.8%)
Pleuritic/non-cardiac chest pain 6 (10%) 14 (12.8%)
UTI 2 (1.7%) 4 (6.7%) 2 (1.7%)

Notes: *Peripheral sensory neuropathy includes related codes (eg, neuropathy peripheral, paresthesia, hypoesthesia, peripheral motor neuropathy, burning sensation, hyporeflexia, peripheral sensorimotor neuropathy).